UBS analyst Jonathan Yong lowered the firm’s price target on Oscar Health (OSCR) to $15 from $17 and keeps a Neutral rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OSCR:
- Oscar Health: Overly Optimistic Growth Assumptions and Rising Medical Cost Risks Drive Sell Rating
- Oscar Health Charts Risky Path Toward 2026 Profitability
- Unusually active option classes on open February 10th
- Oscar Health Projects 2026 Growth Despite 2025 Loss
- CVS, ELV, CNC: Health Insurer Stocks Under Pressure as U.S. Expands Fraud Probe